Prime Medicine, Inc. (PRME)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 2.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 29.54% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
- Prime Medicine stock surges on FDA IND clearance
- CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform. — Am J Hum Genet 2026 May 7 PMID 41923647
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Prime Medicine, Inc..
Full PRME Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.